Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

[at noodls] – CARMIEL, Israel, Dec. 6, 2012 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered into a Clinical Development Agreement with Pfizer Inc. under … more

View todays social media effects on PLX

View the latest stocks trending across Twitter. Click to view dashboard

See who Protalix is hiring next, click here to view